Ipamorelin vs Tesamorelin
Compare the research, key figures and safety notes.
How they differ
Two different types, often paired because they reach the same result — more growth hormone — through different doors. Both are short-acting (well under an hour for tesamorelin, about two hours for ipamorelin). Tesamorelin is a licensed medicine studied at 2 mg a day; ipamorelin's human data is a single blood-level dose.
Side by side
| Measure | Ipamorelin | Tesamorelin |
|---|---|---|
| Category | Growth hormone axis | Growth hormone axis |
| Evidence | A · Human dose research | A · Human dose research |
| Route | Intravenous | Subcutaneous |
| Half-life | 2 h | 0.6 h |
| Typical vial | 5 / 10 mg | 5 / 10 mg |
| Research amount | 100–300 mcg | 1–2 mg |
| Common schedule | Every day | Every day |
| Cycle / break | 8–12 / 4 | 12+ / 4 |
| Studied for | Growth-hormone release | Growth-hormone release |
These amounts and schedules are figures discussed in research and community reports, shared for learning — not a recommendation and not medical advice. A step-by-step dosing schedule exists only where a human trial backs it; the evidence tier tells you which.
Decay curves, overlaid
Each line is scaled to that compound's own first dose, so the chart shows how each one builds up over time — not how the compounds' doses compare to one another, which these different molecules share no common unit for.
How they combine
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.